Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

SRx Health Solutions (SRXH) Finished Goods (2023 - 2025)

Historic Finished Goods for SRx Health Solutions (SRXH) over the last 3 years, with Q3 2025 value amounting to $1.5 million.

  • SRx Health Solutions' Finished Goods fell 5440.78% to $1.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.5 million, marking a year-over-year decrease of 5440.78%. This contributed to the annual value of $1.5 million for FY2025, which is N/A changed from last year.
  • According to the latest figures from Q3 2025, SRx Health Solutions' Finished Goods is $1.5 million, which was down 5440.78% from $4.6 million recorded in Q2 2025.
  • In the past 5 years, SRx Health Solutions' Finished Goods ranged from a high of $5.5 million in Q4 2023 and a low of $1.5 million during Q3 2025
  • Moreover, its 3-year median value for Finished Goods was $3.6 million (2024), whereas its average is $3.6 million.
  • Per our database at Business Quant, SRx Health Solutions' Finished Goods plummeted by 4354.31% in 2024 and then crashed by 5440.78% in 2025.
  • SRx Health Solutions' Finished Goods (Quarter) stood at $5.5 million in 2023, then crashed by 43.54% to $3.1 million in 2024, then plummeted by 50.52% to $1.5 million in 2025.
  • Its Finished Goods stands at $1.5 million for Q3 2025, versus $4.6 million for Q2 2025 and $3.8 million for Q1 2025.